Literature DB >> 10048501

Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.

E Tanaka1.   

Abstract

Drug-drug interactions have become an important issue in health care. It is now realized that many drug-drug interactions can be explained by alterations in the metabolic enzymes that are present in the liver and other extra-hepatic tissues and many of the major pharmacokinetic interactions between drugs are due to hepatic cytochrome P450 (P450 or CYP) enzymes being affected by previous administration of other drugs. After coadministration, some drugs act as potent enzyme inducers, whereas others are inhibitors. However, reports of enzyme inhibition are very much more common. Understanding these mechanisms of enzyme inhibition or induction is extremely important in order to give appropriate multiple-drug therapies. In the future, it may help to identify individuals at greatest risk of drug interactions and adverse events.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10048501     DOI: 10.1046/j.1365-2710.1998.00086.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  33 in total

1.  CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

Review 2.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

3.  Binding site characterization - similarity, promiscuity, and druggability.

Authors:  Christiane Ehrt; Tobias Brinkjost; Oliver Koch
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

Review 4.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Gender aspects in cardiovascular pharmacology.

Authors:  Sabine Oertelt-Prigione; Vera Regitz-Zagrosek
Journal:  J Cardiovasc Transl Res       Date:  2009-06-12       Impact factor: 4.132

6.  Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.

Authors:  Einosuke Tanaka; Yui Takano; Shinichi Inomata; Hidenori Toyooka; Katsuya Honda
Journal:  Eur J Clin Pharmacol       Date:  2004-09-04       Impact factor: 2.953

Review 7.  Clinically important drug interactions with intravenous anaesthetics in older patients.

Authors:  Helge Eilers; Claus Niemann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 9.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

10.  In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.

Authors:  Johanna Weiss; Evelyn Sawa; Klaus-Dieter Riedel; Walter Emil Haefeli; Gerd Mikus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-31       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.